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Abstract
Background: We aimed to investigate the efficacy and safety of botulinum toxin (BT) injections for jerky action tremor of the upper limb.
Methods: We performed an uncontrolled, prospective study of electromyography (EMG)-guided BT injections for jerky, position-specific, upper limb action
tremor. The primary outcome was clinical global impression at 3–6 weeks after baseline.
Results: Eight patients with jerky, position-specific action tremor involving the upper limb were consecutively recruited. After a median follow-up of 4.4 weeks
(interquartile range [IQR] 3.6–6 weeks), four of them rated themselves as ‘‘improved’’ and two as ‘‘much improved.’’ Five of these six subjects reported
improvements in specific activities of daily living (bringing liquids to mouth, feeding, shaving, and dressing). Upper limb subscore of the Fahn–Tolosa–Marin
Tremor Rating Scale (FTM) significantly decreased from 4.5 (4–6) to 3 (2–5) (p50.01).
Discussion: This pilot, prospective cohort study suggests that EMG-guided BT injections may improve jerky, position-specific, upper limb action tremor. Placebo-
controlled studies evaluating larger samples of patients are warranted to confirm these findings.
Keywords: Upper limb tremor, botulinum toxin, action tremor
Citation: Saifee TA, Teodoro T, Erro R, et al. A pilot study of botulinum toxin for jerky, position-specific, upper limb action tremor. Tremor Other Hyperkinet
Mov. 2016; 6. doi: 10.7916/D8T153TQ
1These authors contributed equally to this study.
*To whom correspondence should be addressed. E-mail: carla.cordivari@uclh.nhs.uk
Editor: Elan D. Louis, Yale University, USA
Received: May 19, 2016 Accepted: August 24, 2016 Published: September 29, 2016
Copyright: ’ 2016 Saifee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits
the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered
or transformed.
Funding: Tiago Teodoro receives funding from the grant ‘‘SFRH/SINTD/95267/2013’’, awarded by ‘‘Fundac¸a˜o para a Cieˆncia e a Tecnologia’’.
Financial Disclosures: Roberto Erro received consultancies from Zambon. Mark J Edwards receives royalties from the Oxford University Press for the Oxford Handbook of Parkinson’s
disease and other movement disorders, honoraria from UCB for speaking engagements, and grant funding from NIHR and the Medical Research Council.
Conflict of Interest: Tiago Teodoro has received travel grants from IpsenH.
Ethics Statement: This study was performed in accordance with the ethical standards detailed in the Declaration of Helsinki. The authors’ institutional ethics committee has approved
this study and all patients have provided written informed consent. All patients that appear on video have provided written informed consent; authorization for the videotaping and for
publication of the videotape was provided.
Introduction
The efficacy of pharmacological treatment for upper limb tremors is
often disappointing. In this context, use of botulinum toxin (BT)
injections has had mixed results. Some studies have described signi-
ficant improvement of both tremor and function,1,2 but others have
failed to confirm those benefits.3–5
More recently, a retrospective study of open-label BT injections for
proximal upper limb tremor reported moderate or marked subjective
benefit in 63% patients.6 These encouraging results were related to the
application of an individualized injection strategy in accordance with
tremor characteristics. However, no details were provided about BT
doses and injection sites.
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Here we report a pilot, uncontrolled, prospective cohort study
investigating the efficacy and safety of BT for jerky, position-specific,
upper limb action tremor.
Methods
We recruited consecutive patients presenting with jerky, position-
specific, postural and kinetic tremor of the upper limb to a botulinum
toxin clinic at the National Hospital for Neurology and Neurosurgery
(London), during a period of 10 months. Here we use the term
‘‘position-specific’’ to describe tremor appearance or exacerbation in
particular positions of the upper limbs (e.g. tremor worsening while
slowly supinating or pronating the forearms with the upper limbs
flexed at the elbow). Tremor involved the proximal (i.e. shoulder
abduction/adduction or internal/external rotation) and/or distal
upper limb (forearm pronation/supination or hand tremor). Parti-
cipants were naı¨ve to BT and refractory or intolerant to drug therapy,
or preferred a trial of BT to trials of medication after balancing the
risks and benefits against the alternatives. Non-significant tremor
severity and general contraindications to BT were exclusion criteria.
Our primary outcome measure was clinical global impression
(CGI) at the follow-up visit (i.e. ‘‘much worse,’’ 1; ‘‘worse,’’ 2; ‘‘no
change,’’ 3; ‘‘improved,’’ 4; ‘‘much improved,’’ 5; as rated by the
patient). Secondary outcomes were change in the upper limb tremor
subscore of the Fahn–Tolosa–Marin Tremor Rating Scale (FTM),7
improvement of specific activities of daily living (ADL) (patients were
asked specifically about feeding, bringing liquids to mouth, hygiene,
dressing, writing and working), and occurrence of adverse events
(particularly weakness).
The injection strategy, including muscle selection and dosages, was
individualized according to tremor characteristics. Utilization of elec-
tromyography (EMG) guidance increased the likelihood of injecting
tremulous muscles and sparing non-tremulous ones, thus maximizing
efficacy while avoiding muscle weakness as a side effect. Abo-
botulinum toxin A (DysportH) was used, in a concentration of 20 units
(U) per 0.1 mL. All BT injections were performed by C.C.
Clinical and demographic information was collected during initial
assessment by T.A.S. The follow-up visits were performed 3–6 weeks
after baseline by T.A.S. and C.C. Baseline and follow-up upper limb
FTM subscores were rated by T.T., who analyzed video records
blinded for the time point. Ethics approval and the participant’s
written informed consent were obtained.
Outcome measures were continuous variables, and were expressed
as medians (interquartile range). Differences among those variables,
before and after treatment, were analyzed using Wilcoxon signed-rank
test. The statistical package was STATA version 13 software, and
p,0.05 was considered significant.
Results
We recruited eight patients with predominantly postural and kinetic,
upper limb tremor (five males, three females), with a median age of
70 years (IQR 56–73 years) (Table 1). Tremor was also present at
rest in three patients. Tremor was unilateral or asymmetric in all
participants. Proximal tremor was predominant, but the shoulder and
forearm were involved in most subjects. Tremor was jerky in character
in all participants. Moreover, tremor also showed position-specificity in
all subjects. Indeed, we observed significant tremor worsening when
we asked the patients to slowly supinate or pronate the forearms with
the upper limbs flexed at the elbow. Four subjects were non-responsive
and/or intolerant to previous drug treatments and another four were
treatment naı¨ve. Two patients had head tremor and one had mild
cervical dystonia as additional neurological features.
A total of 10 upper limbs were treated, and 14 individual muscles
injected. Our approach was to inject, in an individualized fashion, the
following muscles according to the clinical presentation: shoulder
abduction movement, deltoid (one) and supraspinatus (one); shoulder
adduction, pectoralis major (one) and teres major (one) (also arm
internal rotation); scapular rotation, trapezius (one); shoulder external
rotation, infraspinatus (five) and teres minor (one); arm internal rota-
tion, latissimus dorsi (one) and subscapularis (one); forearm supination,
supinator (five); forearm pronation, pronator teres (five) and pronator
quadratus (five); wrist extension/abduction, extensor carpi radialis
(two); wrist flexion/adduction, flexor carpi ulnaris (one) (Table 1).
The median total dosage per participant of DysportH was 205 IU
(190–300 IU) (Table 2).
After a median follow-up of 4.4 weeks (IQR 3.6–6 weeks), four of
the eight participants reported themselves to be ‘‘improved’’ and two
‘‘much improved.’’ The two other subjects reported no change in
tremor. Importantly, five of the six subjects who reported improve-
ment also described functional benefit in specific ADL, including
bringing liquids to the mouth (four), feeding (three), dressing (one),
shaving (one). FTM upper limb subscores (possible range 0–12)
significantly decreased from a median of 4.5 (4–6) to 3 (2–5) (p50.01,
Wilcoxon signed-rank test).
Three subjects experienced muscle weakness following injections,
but this was only clinically significant in one participant whose weak-
ness affected the shoulder (Table 2). Our sample is too small to
correlate efficacy and safety with specific clinical patterns or injection
strategies.
Discussion
In this pilot, prospective cohort study we investigated EMG-guided
BT injections for jerky, position-specific, upper limb action tremor. Six
out of the eight patients reported a beneficial effect. In five of these,
it included improvement in one or more ADL, for example bringing
liquids to the mouth and feeding. Efficacy was further supported by a
significant decrease in the FTM upper limb subscore.
Importantly, BT was well tolerated in our cohort, with significant
weakness in only one patient. EMG guidance and an individualized
treatment likely contributed to there being limited adverse effects.
Despite the small sample size and the open-label, uncontrolled
administration of BT, these results are encouraging. Significantly, this
is the first prospective study evaluating BT for jerky, postural, and
kinetic tremor of the upper limb. Moreover, our sample included
medication-refractory patients with proximal ‘‘wing-beating’’ tremor,
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which can be very disabling by interfering with bringing food or liquids
to the mouth.6
BT injections have a fairly accepted role in managing head tremor,
tremulous spasmodic dysphonia, and primary writing tremor.8,9
However, studies of the effect of BT on other upper limb tremor
types have had heterogeneous results in terms of functional disability.
Although a placebo-controlled trial in multiple sclerosis-associated
tremor1 and a case report in anti-MAG neuropathy-related tremor2
described significant improvement of both tremor and function, other
studies of BT in essential or parkinsonian tremor failed to demonstrate
functional improvement3,4 and/or to show change in objective tremor
measures.5
More recently, a retrospective, open-label study of BT for proximal
upper limb tremor reported moderate or marked benefit in 63% of
19 patients.6 The adoption of an individualized injection strategy was
most likely to be related to this better outcome.6 Similarly, we applied
an individualized strategy of BT injection, in accordance with tremor
characteristics.
Dystonia was present in only one patient in our cohort, and did not
affect the upper limb (Table 1). However, upper limb tremor in study
participants had clinical characteristics akin to dystonic tremor/tremor
associated with dystonia.10 Tremor was ‘‘jerky’’ in character, position
specific, predominantly postural/kinetic, and unilateral/asymmetric.
Although dystonic tremor is classically defined by the coexistence of
dystonia in the same body part,11 recent studies suggest that patients
can have isolated tremor with dystonic features but without overt
dystonia12,13 and develop dystonia only later in life.14 In the absence of
reliable biomarkers for dystonic tremor, we adopted a descriptive label
of ‘‘jerky, position-specific, upper limb action tremor,’’ but highlighting
the phenomenological similarities between dystonic tremor10 and that
of the patients described here. This is relevant because evidence to
guide treatment of dystonic tremor is scarce, and the efficacy of drug
treatment generally disappointing.8 Interestingly, in a previous retro-
spective study of individually tailored BT injections for upper limb
tremor, significant improvements were observed in four out of six
patients with dystonic tremor.6
We acknowledge that our study has significant methodological
limitations. These include a small sample size, the absence of a control
group and the open-label nature of the intervention.
Nevertheless, the existence of a common trend among the follow-up
clinical global impression of the patients, blinded tremor rating scale
scores, and modification of ADL hints at a genuine beneficial effect.
In conclusion, this small, open-label and uncontrolled prospective
cohort study suggests that individualized EMG-guided BT injections
may reduce tremor and improve function in patients with jerky,
position-specific, upper limb action tremor, with few side effects.
We believe that these findings should encourage further investigation
about the role of individualized BT treatment for upper limb action
tremor, through the performance of randomized, controlled, well-
powered clinical trials.
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